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ABSTRACT
The feasibility and required sensitivity of circulating free DNA (cfDNA)-based 
detection methods in second-line epidermal growth factor receptor-tyrosine kinase 
inhibitor (EGFR-TKI) treatment are not well elucidated. We examined T790M and 
other activating mutations of EGFR by cfDNA to assess the clinical usability. In 45 
non-small cell lung cancer (NSCLC) patients harboring activating EGFR mutations, 
cfDNAs were prepared from the plasma samples. EGFR mutations in cfDNA were 
detected using highly sensitive methods and originally developed assays and these 
results were compared to tissue-based definitive diagnoses. The specificity of each 
cfDNA-based method ranged 96–100% whereas the sensitivity ranged 56–67%, 
indicating its low pseudo-positive rate. In EGFR-TKI failure cohort, 41–46% samples 
were positive for T790M by each cfDNA-based method, which was comparable to 
re-biopsy tissue-based T790M positive rates in literature. The concordance of the 
results for each EGFR mutation ranged from 83–95%. In eight patients, the results 
of the cfDNA-based assays and re-biopsy-derived tissue-based test were compared. 
The observed overall agreement ranged in 50–63% in T790M, and in 63–100% in 
activating EGFR mutations. In this study, we have newly developed three types of 
assay which have enough sensitivity to detect cfDNA. We also detected T790M in 44% 
of patients who failed prior EGFR-TKI treatment, indicating that cfDNA-based assay 
has clinical relevance for detecting acquired mutations of EGFR. 
www.oncotarget.com                                             Oncotarget, 2019, Vol. 10, (No. 38), pp: 3654-3666
INTRODUCTION
Lung cancer is the leading cause of cancer 
death worldwide, and the associated mortality rate is 
still increasing [1]. Over the last decade, molecular-
based researches have brought major breakthroughs in 
diagnosis and management of lung cancer, particularly 
for the non-small cell lung cancer (NSCLC). NSCLC 
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patients harboring activating mutations in epidermal 
growth factor receptor (EGFR), such as exon 19 
deletions (Del 19) or L858R, show significant benefit 
with treatment of EGFR-tyrosine kinase inhibitors 
(EGFR-TKIs) [2–4]. However, most patients acquire 
resistance after 9–12 months of EGFR-TKI treatments. 
Among several resistant mechanisms which have 
been revealed by pre-clinical and clinical studies 
[5, 6], T790M acquisition occurred in about half of 
patients who received first-line EGFR-TKI treatment 
[5]. Recently developed third-generation EGFR-TKI, 
osimertinib, which covalently binds to T790M-harboring 
mutant EGFR, approved as second-line EGFR-TKI 
worldwide including Japan [7]. To select second-line 
therapy, re-biopsy is required to identify T790M on 
disease progression after first-line EGFR-TKI treatment. 
The conventional diagnostics such as real-time PCR for 
detecting EGFR mutations were designed to use biopsied 
formalin-fixed paraffin-embedded (FFPE) specimens as 
an analytical source of genomic DNA. However, when 
disease progression is observed after treatment with 
EGFR-TKIs, histology samples can not be obtained in 
some patients because of the site of relapse or metastasis 
and invasiveness. Chouaid et al. reported that 18% of 
patients could not undergo re-biopsy, mainly because 
they were receiving anticoagulation therapy, which was 
considered to be a contraindication [8]. Moreover, in 
patients who undergo re-biopsy at disease progression, 
collecting histology samples becomes more difficult 
because of an increased need to perform sample 
collection from various metastatic lesions, including 
body cavity fluid [9, 10].
Recently, plasma circulating free DNA (cfDNA) 
is used as a less-invasive analytical source of cancer 
patients including NSCLC [11]. cfDNA contains 
circulating tumor derived DNA, which had shed into 
the vasculature from tumor tissues [12]. Most part of 
cfDNA derived from normal tissue, the high background 
complicates the nucleic acid-based analyses by a 
conventional method. The limit of detection of EGFR 
T790M nucleic acid sequence are reported to be 2.0–3.0% 
for Cobas® EGFR Mutation Test v2 [13] and 7.02% for 
Therascreen EGFR plasma RGQ [14]. There are limited 
reports demonstrating clinical feasibility of detecting 
T790M from cfDNA in NSCLC patients who failed prior 
EGFR-TKI treatment compared to those reporting about 
major activating mutations like Del 19 or L858R [15]. 
Besides the sensitivity issue of detecting cfDNA that 
mentioned above, the conceivable genetic heterogeneities 
of metastatic foci further complicate the discussions 
for concordance between cfDNA and tissue biopsy in 
detecting acquired mutations.
In the present study, we examined the cfDNA of 
patients for T790M and other activating EGFR mutations 
to assess the clinical usability of such data for the 
diagnostic purposes. We report here that the cfDNA-based 
assay showed good performance in both concordance with 
a conventional method and frequency of detecting T790M.
RESULTS
Patient characteristics
The clinical characteristics of 45 patients are listed 
in Table 1. All but one (97.8%) had adenocarcinoma. 
L858R was the most common activating EGFR mutation 
(51.1%), followed by Del 19 (44.4%). Eighteen (40.0%) 
were EGFR-TKI naïve (EGFR-TKI naïve group), while 
27 (60.0%) had been treated with one or more EGFR-TKIs 
(EGFR-TKI failure group).
Extraction of cfDNA from patient plasma
The isolation of cfDNA was performed from 
10 mL whole blood specimen of each patient, and the 
calculated DNA amounts were 3.3–293.4 ng (median: 
19.1 ng) (Supplementary Table 1). There are no significant 
correlations between age, gender, smoking status, or prior 
EGFR-TKI treatment status and isolated cfDNA amounts 
(data not shown). In 38 patients with target lesions, there 
was a significant positive correlation between the sum of 
diameters of target lesions and isolated cfDNA amounts 
(Figure 1). We further analyzed prospectively the clinical 
outcome of registered patients, there was a significant 
negative correlation between progression free survivals 
(PFSs) of all kind of regimens administered immediately 
after cfDNA isolation and the amounts of cfDNA (N = 44; 
Figure 2A). Similarly, a significant negative correlation 
with cfDNA amounts was observed in patients received 
EGFR-TKI treatment immediately after cfDNA isolation 
(Figure 2B), but not in patients received cytotoxic agents 
(data not shown).
Evaluation of the detection limit of cfDNA 
analysis methods
In more than 0.05% of mutation frequency, NGS 
(next generation sequencing) and F-PHFA (fluorescence 
resonance energy transfer-based preferential homoduplex 
formation assay) could detect all eligible 24 EGFR 
mutations in exon 18–21 and ddPCR (droplet digital 
PCR) could also detect all eligible 8 EGFR mutations 
in exon 19–21 at least one time by repeated analysis 
(Supplementary Table 2). Thus, the limit of detection 
for EGFR mutations in cfDNA from NSCLC patients 
were 0.05% in all three technologies, NGS, F-PHFA and 
ddPCR, which is comparable to previous findings [16].
EGFR mutation detection by cfDNA-based 
methods
We performed EGFR mutation detection in patient-
derived cfDNA with originally developed methods 
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and a reference method (NGS). F-PHFA is possible 
to distinguish preset 19 types of variations of Del 19, 
and we detected nine types of deletions individually. 
We performed ultra-deep amplicon sequencing using 
NGS with >100,000 reads per an amplicon. Thus, 
NGS revealed the existence of several types of Del 
19 including type unlisted in the catalogue of somatic 
mutations in cancer (COSMIC). These results suggested 
complicated aspects in variety of short deletions in 
EGFR. These tests were performed successfully in all 
cfDNA samples, except for ddPCR in a particular case 
(Supplementary Table 1).
Concordance between cfDNA-based methods 
and a conventional method in activating EGFR 
mutations
We evaluated the concordance between each 
cfDNA-based method and a conventional method in 
activating EGFR mutations. The concordance in Del 19 
was considerably high (89–93%) compared with that in 
L858R (67–78%). The sensitivities and specificities of 
cfDNA-based methods in detection of common mutations 
were also determined. The specificity of each method 
ranged 96–100%, whereas the sensitivity ranged 56–67% 
Table 1: Patient characteristics
No. 45
Age (Year)



















Adenosquamous carcinoma 1 (2.2%)
EGFR mutation status







ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; EGFR-TKI, epidermal growth 
factor receptor-tyrosine kinase inhibitor; Del 19, exon 19 deletions.
aNaïve, patients who had no prior treatment with EGFR-TKI.
bFailure, patients whose disease progressed after EGFR-TKI treatment.
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(Supplementary Table 3, Table 2), indicating the character 
of cfDNA-based methods having less risk in pseudo-
positivity.
Evaluation of the sensitivities of cfDNA-based 
methods to detect T790M
We performed cfDNA-based methods to detect 
T790M in all cfDNA samples (Table 3). In EGFR-TKI 
failure group (N = 27), 12 (44%) resulted T790M positive 
by F-PHFA. By NGS, ddPCR and real-time PCR, the 
T790M positive rates in EGFR-TKI failure cohort were 
41%, 37%, and 46%, respectively. In EGFR-TKI naïve 
group (N = 18), no T790M were detected by all methods 
except for NGS (11%). Sixteen of 27 (59%) showed T790M 
positive by at least one method in EGFR-TKI failure group, 
which is comparable to those of reported re-biopsy tissue-
based T790M positive rates in literature [5, 6].
Concordance among four cfDNA-based methods 
to detect each EGFR mutation
We examined the concordance of the results for each 
EGFR mutation spot by each pair of detection methods. 
Figure 1: Correlation between isolated cfDNA amounts and the sum of diameters of target lesions. In 38 NSCLC patients 
with target lesions, there was a significant positive correlation between isolated cfDNA amounts and the sum of diameters of target lesions 
(P < 0.01, Spearman’s rank correlation test).
Figure 2: Correlations between isolated cfDNA amounts and the clinical outcomes of enrolled patients. (A) There was a 
significant negative correlation between the cfDNA amounts and the PFSs of all kind of regimens administered immediately after cfDNA 
isolation (N = 44; P < 0.01, Spearman’s rank correlation test). (B) There was a significant negative correlation between the cfDNA amounts 
and the PFSs of EGFR-TKI administered immediately after cfDNA isolation (P < 0.01, Spearman’s rank correlation test), but not those of 
cytotoxic agents (data not shown).
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Except for ddPCR, all data from 45 patients are included 
to calculating the concordance. The concordance rate 
ranged from 83–95% (Table 4), suggesting that these newly 
developed three methods in this research, F-PHFA, ddPCR 
and real-time PCR, have comparable sensitivity as formerly 
reported method by NGS [17] for detecting EGFR mutation.




Alla Del 19 L858R
N Rate (%) N Rate (%) N Rate (%)
  Concordanceb 45 25/45 (56) 45 41/45 (91) 45 30/45 (67)
  Sensitivityc 43 24/43 (56) 20 16/20 (80) 23 8/23 (35)
  Specificityd 45 45/45 (100) 25 25/25 (100) 22 22/22 (100)
ddPCR
  Variables
All Del 19 L858R
N Rate (%) N Rate (%) N Rate (%)
  Concordance 44 26/44 (59) 44 39/44 (89) 44 32/45 (71)
  Sensitivity 42 25/42 (60) 19 14/19 (74) 23 11/23 (48)
  Specificity 44 44/44 (100) 25 25/25 (100) 21 21/21 (100)
Real-time PCR
  Variables
All Del 19 L858R
N Rate (%) N Rate (%) N Rate (%)
  Concordance 43 26/43 (60) 43 40/43 (93) 43 31/43 (72)
  Sensitivity 41 26/41 (63) 19 16/19 (84) 22 10/22 (45)
  Specificity 43 43/43 (100) 24 24/24 (100) 21 21/21 (100)
NGS
  Variables
All Del 19 L858R
N Rate (%) N Rate (%) N Rate (%)
  Concordance 45 29/45 (64) 45 40/45 (89) 45 35/45 (78)
  Sensitivity 43 29/43 (67) 20 16/20 (80) 23 13/23 (57)
  Specificity 45 44/45 (98) 25 24/25 (96) 22 22/22 (100)
EGFR mutations in plasma cfDNA and tumor DNA were assesed by plasma cfDNA-based high-performance assays and 
biopsy tissue-derived tumor DNA-based conventional assay (PNA-LNA PCR clamp method), respectively.
a“All” activating EGFR mutations include Del 19, L858R, G719X and L861Q.
bConcordance was calculated by dividing number of concordant samples by number of all analyzed samples in each 
EGFR mutation status between plasma cfDNA and tumor DNA.
cSensitivity was calculated by the following equation:
Sensitivity (%) =
number of EGFR mutation positive assesed by cfDNA-based high-
performance assay
×100
number of EGFR mutation positive assesed by tumor DNA-based 
conventional assay
dSpecificity was calculated by the following equation:
Specificity (%) =
number of EGFR mutation negative assesed by cfDNA-based high-
performance assay
×100
number of EGFR mutation negative assesed by tumor DNA-based 
conventional assay
EGFR, epidermal growth factor receptor; cfDNA, circulating free DNA; Del 19, exon 19 deletions; 
F-PHFA, fluorescence resonance energy transfer-based preferential homoduplex formation assay; 
ddPCR, droplet digital PCR; NGS, next generation sequencing.
Oncotarget3659www.oncotarget.com
The concordance, sensitivity and specificity of 
EGFR mutation status by high-performance 
assays between plasma cfDNA and biopsy-
derived genomic DNA
In eight patients who were performed re-biopsy 
during the period of this research, the results of four 
cfDNA-based assays and re-biopsy-derived tissue-based 
test were compared (Table 5). The overall agreement 
ranged in 50–63% in T790M between each cfDNA-
based assay and tissue-based test. In contrast, the overall 
agreement ranged in 63–100% in activating EGFR 
mutations, which may reflect the difference of tumor 
heterogeneities rather than assay sensitivity between 
activating mutations and acquired mutations. In addition, 
to validate these newly developed assays in tissue-derived 
genomic DNA, we explored these cfDNA-based assays 
(F-PHFA, NGS and real-time PCR) using genomic DNA 
extracted from FFPE samples obtained by the initial 
biopsy in 29 patients. NGS and real-time PCR showed the 
overall agreement ranged in 97–100% in every mutation 
spot of EGFR. F-PHFA showed slight lower agreement 
score than the other two methods (Table 6), indicates 
that F-PHFA needs some adjustment of sensitivity for 
application in genomic DNA, far greater amount than 
cfDNA.
DISCUSSION
In the present study, we have newly developed three 
types of assay which have enough sensitivity to detect 
cfDNA. We confirmed the high concordance of assay 
results between these assays and formerly reported method 
by NGS in each EGFR mutation spot. Three types of assay, 
F-PHFA, ddPCR, and real-time PCR have an advantage of 
assay turnover within one day after extraction of cfDNA 
from patient plasma, whereas NGS needs two or three 
weeks to complete assay procedure. At a point of view 
of quantification, NGS and ddPCR are superior to real-
time PCR and F-PHFA, due to suppression of amplifying 
wild-type copies by clamping reagents. NGS and ddPCR 
needs exclusive equipment, whereas real-time PCR and 
F-PHFA can be conducted with widespread real-time PCR 
equipment. Among these, real-time PCR method required 
only a real-time PCR instrument which is relatively 
inexpensive and well widespread among clinical site 
and laboratories. Furthermore, we utilized BNA (bridged 
nucleic acid) as clamping reagents and probes in real-time 
PCR procedure to realize more mutation-specific and 
stable detection assay, so that we can detect T790M in 
44% of patients who failed prior EGFR-TKI treatment. 
It indicates that cfDNA-based assay with real-time PCR 
has clinical relevance for detecting acquired mutation 




F-PHFA ddPCR Real-time PCR NGS Any
N Rate (%) N Rate (%) N Rate (%) N Rate (%) N Rate (%)
Failurea 27 12/27 (44) 27 10/27 (37) 26 12/26 (46) 27 11/27 (41) 27 16/27 (59)
Naïveb 18 0/18 (0) 17 0/17 (0) 17 1/17 (6) 18 2/18 (11) 18 2/18 (11)
Total 45 12/45 (27) 44 10/44 (23) 43 13/43 (30) 45 13/45 (29) 45 18/45 (40)
aFailure, patients whose disease progressed after EGFR-TKI treatment.
bNaïve, patients who had no prior treatment with EGFR-TKI.
Table 4: Concordance among four cfDNA-based high-performance assays to detect EGFR mutations
Methods
T790M Del 19 L858R
N Rate (%) N Rate (%) N Rate (%)
F-PHFA/ddPCR 44 38/44 (86) 44 41/44 (93) 44 41/44 (93)
F-PHFA/Real-time PCR 43 37/43 (86) 43 41/43 (95) 43 41/43 (95)
F-PHFA/NGS 45 38/45 (84) 45 42/45 (93) 45 40/45 (89)
ddPCR/Real-time PCR 42 35/42 (83) 42 41/42 (98) 42 40/42 (95)
ddPCR/NGS 44 37/44 (84) 44 42/44 (96) 44 40/44 (91)
Real-time PCR/NGS 43 37/43 (86) 43 43/43 (100) 43 41/43 (95)
Concordance was calculated by dividing number of concordant samples by number of all analyzed samples in each EGFR 
mutation status among two different cfDNA-based high-performance assays.
cfDNA, circulating free DNA; EGFR, epidermal growth factor receptor; Del 19, exon 19 deletions; 
F-PHFA, fluorescence resonance energy transfer-based preferential homoduplex formation assay; ddPCR, droplet digital PCR; 
NGS, next generation sequencing.
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Table 5: The concordance, sensitivity and specificity of EGFR mutation status by high-performance assays between 
plasma cfDNA and re-biopsy tisssue-derived tumor DNA in eight NSCLC patients who were performed re-biopsy
F-PHFA
Variables
T790M Del 19 L858R
N Rate (%) N Rate (%) N Rate (%)
Concordancea 8 5/8 (63) 8 8/8 (100) 8 5/8 (63)
Sensitivityb 4 3/4 (75) 5 5/5 (100) 3 0/3 (0)
Specificityc 4 2/4 (50) 3 3/3 (100) 5 5/5 (100)
ddPCR
Variables
T790M Del 19 L858R
N Rate (%) N Rate (%) N Rate (%)
Concordance 8 4/8 (50) 8 7/8 (88) 8 6/8 (75)
Sensitivity 4 1/4 (25) 5 4/5 (80) 3 1/3 (33)
Specificity 4 3/4 (75) 3 3/3 (100) 5 5/5 (100)
Real-time PCR
Variables
T790M Del 19 L858R
N Rate (%) N Rate (%) N Rate (%)
Concordance 8 4/8 (50) 8 7/8 (88) 8 6/8 (75)
Sensitivity 4 2/4 (50) 5 4/5 (80) 3 1/3 (33)
Specificity 4 2/4 (50) 3 3/3 (100) 5 5/5 (100)
NGS
Variables
T790M Del 19 L858R
N Rate (%) N Rate (%) N Rate (%)
Concordance 8 4/8 (50) 8 7/8 (88) 8 6/8 (75)
Sensitivity 4 2/4 (50) 5 4/5 (80) 3 1/3 (33)
Specificity 4 2/4 (50) 3 3/3 (100) 5 5/5 (100)
In eight NSCLC patients who were performed re-biopsy, EGFR mutations in plasma cfDNA and tumor DNA were 
assesed  by plasma cfDNA-based high-performance assays and re-biopsy tissue-derived tumor DNA-based high-
performance assays, respectively.
aConcordance was calculated by dividing number of concordant samples by number of all analyzed samples in each 
EGFR mutation status between plasma cfDNA and re-biopsy tisssue-derived tumor DNA.
bSensitivity was calculated by the following equation: 
Sensitivity (%) =
number of EGFR mutation positive assesed by tumor DNA-based high-
performance assay
×100
number of EGFR mutation positive assesed by tumor DNA-based high-
performance assay
cSpecificity was calculated by the following equation:
Specificity (%) =
number of EGFR mutation negative assesed by cfDNA-based high-
performance assay
×100
number of EGFR mutation negative assesed by tumor DNA-based high-
performance assay
EGFR, epidermal growth factor receptor; cfDNA, circulating free DNA;
NSCLC, non-small cell lung cancer; Del 19, exon 19 deletions;
F-PHFA, fluorescence resonance energy transfer-based preferential homoduplex formation assay; 
ddPCR, droplet digital PCR; NGS, next generation sequencing.
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of EGFR. The cobas® EGFR Mutation Test v2, which 
has been recently approved for the detection of EGFR 
mutations in plasma, is reported to have a sensitivity 
of 5%, i.e., it can detect 5% EGFR mutant alleles in a 
background of 95% wild-type alleles [18]. While ddPCR 
and NGS have not been approved, they are widely used 
in research settings due to their quantitative advantage 
and superior sensitivity (0.04–0.1%) [16]. In this study, 
we demonstrated the limit of detection of 0.05% to 
detect EGFR mutations in cfDNA from NSCLC patients 
in NGS, F-PHFA and ddPCR, which is comparable to 
aforementioned previous findings [16] and superior to the 
commercially available cobas® EGFR Mutation Test v2. 
Given the high sensitivities, originally developed three 
methods might be promising candidates for the detection 
of EGFR mutation in cfDNA from NSCLC patients. We 
also showed that the expected amount of cfDNA in patient 
blood is about 0.3–30 ng/mL (3.3–293.4 ng per 10 mL of 
whole blood), which indicated that patient bloods contain 
about 50 to 5,000 genomic equivalent (copies) per mL. 
In clinical practice, the limit of detection of 0.05% is 
considered to be enough to detect 3–4 copies of mutation 
Table 6: The concordance, sensitivity and specificity of EGFR mutation status by high-performance assays between 
plasma cfDNA and initial biopsy tisssue-derived tumor DNA in 29 NSCLC patients who were not performed re-biopsy
F-PHFA
Variables
T790M Del 19 L858R G719X
N Rate (%) N Rate (%) N Rate (%) N Rate (%)
Concordancea 29 20/29 (69) 29 27/29 (93) 29 25/29 (86) 29 29/29 (100)
Sensitivityb 0 0/0 10 9/10 (90) 17 13/17 (76) 2 2/2 (100)
Specificityc 29 20/29 (69) 19 18/19 (95) 12 12/12 (100) 27 27/27 (100)
Real-time PCR
Variables
T790M Del 19 L858R G719X
N Rate (%) N Rate (%) N Rate (%) N Rate (%)
Concordance 29 29/29 (100) 29 29/29 (100) 29 28/29 (97) 3 3/3 (100)
Sensitivity 0 0/0 10 10/10 (100) 17 16/17 (94) 2 2/2 (100)
Specificity 29 29/29 (100) 19 29/29 (100) 12 12/12 (100) 1 1/1 (100)
NGS
Variables
T790M Del 19 L858R G719X
N Rate (%) N Rate (%) N Rate (%) N Rate (%)
Concordance 29 28/29 (97) 29 29/29 (100) 29 29/29 (100) 29 29/29 (100)
Sensitivity 0 0/0 10 10/10 (100) 17 17/17 (100) 2 2/2 (100)
Specificity 29 28/29 (97) 19 19/19 (100) 12 12/12 (100) 27 27/27 (100)
In 29 NSCLC patients who were not performed re-biopsy, EGFR mutations in plasma cfDNA and tumor DNA were 
assesed  by plasma cfDNA-based high-performance assays and initial biopsy tissue-derived tumor DNA-based high-
performance assays, respectively.
aConcordance was calculated by dividing number of concordant samples by number of all analyzed samples in each 
EGFR mutation status between plasma cfDNA and re-biopsy tisssue-derived tumor DNA.
bSensitivity was calculated by the following equation:
Sensitivity (%) =
number of EGFR mutation positive assesed by cfDNA-based high-performance assay
× 100number of EGFR mutation positive assesed by tumor DNA-based high-performance 
assay
cSpecificity was calculated by the following equation:
Specificity (%) =
number of EGFR mutation negative assesed by cfDNA-based high-performance assay
× 100number of EGFR mutation negative assesed by tumor DNA-based high-performance 
assay
EGFR, epidermal growth factor receptor; cfDNA, circulating free DNA;
NSCLC, non-small cell lung cancer; Del 19, exon 19 deletions;
F-PHFA, fluorescence resonance energy transfer-based preferential homoduplex formation assay; NGS, next generation 
sequencing.
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mixed with wild type genomic DNA in patient bloods. 
Based on binominal statistical distribution, this number of 
copies can be regarded as a lower limit for discussion of 
quantitativeness.
A number of clinical researches were reported that 
aim to detect activating EGFR mutations using cfDNA 
from plasma of NSCLC patients. Meta-analysis which 
comparing paired cfDNA and tissue-based assay results 
concluded that EGFR mutation detection by cfDNA is 
of adequate diagnostic accuracy [17]. On the other hand, 
there is still room for argument about diagnostic value 
of cfDNA-based assay detecting T790M in NSCLC 
patients who failed prior EGFR-TKI treatment. In this 
study, we compared paired cfDNA and tissue-based 
assay results in patients who were conducted re-biopsy. 
The concordance for T790M detection was 63% in case 
of F-PHFA. Both pseudo-positive (cfDNA positive, re-
biopsy tissue negative) and pseudo-negative (cfDNA 
negative, re-biopsy tissue positive) were observed, which 
were considered to result from biological features of 
cfDNA, such as the tumor heterogeneity of each cancer 
nodule that is considered to have greater impact in case 
of acquired resistance mutation for EGFR-TKI treatment 
[19], influence of drug treatment on cfDNA shedding in 
tumor sites and tumor size. Su et al. reported that NGS 
was highly sensitive in detecting T790M even in EGFR-
TKI naïve NSCLC patients, which is consistent with our 
findings in this study. They also demonstrated that the 
existence of pretreatment T790M in EGFR-TKI naïve 
NSCLC patients predicted shorter EGFR-TKI response 
duration [20], indicating that NGS might be a useful tool 
for the prediction of the efficacy of EGFR-TKI.
There is a controversy about the association between 
cfDNA status and clinical outcomes of cancer patients. 
Several reports indicated that there is no correlation 
between cfDNA amounts and tumor burdens including 
NSCLC [21, 22]. We found a clear correlation between 
extracted cfDNA amounts from patient’s plasma and 
the sum of diameters of target lesions. In this study, all 
were Japanese patients with activating EGFR mutations, 
and all but one (97.8%) had adenocarcinoma and 43 
of 45 (95.6%) had distant metastases. The uniformed 
pathological background might result in the significant 
correlation. Ohira et al. reported that the mutation 
detection with cfDNA depended on the T factor in stage 
IA-IIIA NSCLC patients. They found that no mutation 
was detected in cfDNA of patients at T1a-T2a, with all 
such mutations being found in those at T2b or T3 [23], 
indicating that cfDNA might be a beneficial option for 
mutation detection in NSCLC patients with T factors of 
T2b or higher.
Recently, the third-generation EGFR-TKI which 
have clinical efficacy on patients harboring T790M had 
launched [7]. The tissue-based assay as well as cfDNA-
based assay had approved to detect T790M in NSCLC 
patients who failed prior EGFR-TKI treatment. Several 
reports referred to emergence of C797S in cfDNA 
after second-line osimertinib treatment as a resistance 
mechanism [24]. When osimertinib is approved in first-
line treatment of EGFR mutation-positive advanced 
NSCLC, C797S detection in cfDNA will become 
important with less life-threating in sample acquisition. 
Our technologies for cfDNA analysis have capability for 
applying to not only C797S but also any other mutation 
reported in various tumor types. We have started to 
develop assays to detect such mutations recently reported 
in third-generation EGFR-TKIs.
There is known single nucleotide polymorphism 
(SNP) just upstream coding region of T790 in exon 20 
of EGFR. In our newly developed assay, real-time PCR 
is affected by this SNP. In development of real-time 
PCR method, we designed two types of probe, which 
correspond to each SNP, to solve this problem. In a 
particular case, detailed bioinformatics analysis in ultra-
deep sequencing reveals that K860I and L858R together 
in the same allele (ie, cis). Mutation specific primer/
probe depending assay such as F-PHFA or ddPCR called 
L858R wild type in this case. We designed real-time 
PCR probe on EGFR gene avoiding codon K860I, so 
that real-time PCR called L858R positive in this case 
successfully.
We have developed three types of assays detecting 
minor type of activating mutations, G719A/S/C and 
L861Q, except for real-time PCR. Numbers of the enrolled 
patient harboring minor mutations were quite limited. In 
two patients harboring G719A detected by a conventional 
method, we could detect G719A in cfDNA in one patient. 
In one patient who had enrolled with L861Q, we could not 
find mutate signal in cfDNA by any methods. To discuss 
the success or failure of development for minor mutation 
detection assay, further investigation with clinical sample 
is needed.
There were several limitations in this study. First, 
only nine of 45 patients (20.0%) were treatment-naïve and 
most patients were enrolled while undergoing treatment. 
Second, the parallel analysis of tumor tissue and plasma 
could not be performed in eight of 45 patients (17.8%). 
Third, the sample size was small and a larger follow-up 
study is required to validate our findings.
In this report, we showed successful detection of 
activating and acquired EGFR mutations in NSCLC 
patients derived cfDNA sample by originally developed 
three types of mutation detection assays. Utilizing 
artificial nucleic acid, our technologies have suitable 
features for application as clinical examinations, short 
turnaround time and requirement of wide-spread real-
time PCR equipment. Given the superior sensitivities 
as compared with commercially available test, our three 
technologies are promising methods for the detection of 
EGFR mutation in cfDNA from NSCLC patients.
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MATERIALS AND METHODS
Patients and study design
From February 2014 to December 2015, 45 
patients were prospectively enrolled in this study. The 
criteria for patient eligibility included histologically or 
cytologically confirmed NSCLC, harboring activating 
EGFR mutations, stage IIIB/IV or postoperative recurrent 
diseases. Patients who were judged to be inappropriate for 
enrollment by physician’s discretion were excluded from 
this study. The histological type and the staging of lung 
cancer were defined according to the WHO classification 
and the Union for International Cancer Control-TNM 
Classifications (Seventh Edition), respectively. The 
performance status was assessed according to the Eastern 
Cooperative Oncology Group (ECOG) classification. 
Tumor tissue biopsies were performed for the definite 
diagnosis of lung cancer and the obtained tissue samples 
were used for the detection of EGFR mutation by a 
clinically available PNA-LNA PCR clamp method. The 
statement on consent to participate in this study was 
obtained from patients by using written informed consent 
form. The study was performed in accordance with the 
Declaration of Helsinki, and the study protocol was 
approved by the Institutional Review Board of Tokushima 
University Hospital (approval date: 2013/12/20, approval 
number: 1859).
At a time of beginning our research, high-sensitive 
method designed for cfDNA analysis have been limited, 
in addition, the cobas® EGFR Mutation Test v2 was not 
approved in Japan. We therefore originally developed 
three types of high-sensitive method to sufficiently 
detect activating mutation of EGFR including Del 19, 
L858R, G719X, L861Q and T790M in cfDNA. We 
prepared cfDNA from plasma samples of NSCLC patients 
harboring EGFR mutations, followed by analyzing EGFR 
mutation in cfDNA by these methods. Performances of 
the methods on detecting activating mutations in cfDNA 
were confirmed by comparing results to the EGFR 
mutation status evaluated by a conventional method. 
The frequency of detected T790M was assessed in the 
population of disease progressed after treatment of EGFR-
TKIs. Tumor re-biopsies were performed in eight patients 
who registered in this study, which enabled to compare 
the detected mutation status between cfDNA and tissue. 
As the analytical reference of developed methods, we 
utilized ultra-deep sequencing method [25], with slight 
modification in bioinformatics procedure.
Plasma preparation and cfDNA isolation, purity 
evaluation
Blood samples (10 mL) that were collected in EDTA 
tubes were processed within three hours after collection 
and were centrifuged to separate the plasma from the 
peripheral-blood cells. DNA was extracted from aliquots 
of plasma with the use of the QIAamp circulating nucleic 
acid kit (Qiagen, Venlo, Netherlands). The amounts of 
cfDNA were quantified by assay utilized PicoGreen 
(Turner BioSystems, Sunnyvale, CA). The purities of 
cfDNA were evaluated by using Bioanalyzer (Agilent, 
Santa Clara, CA).
Genomic DNA isolation from FFPE tissues
In 37 of 45 NSCLC patients whose residual 
histological samples were enough for further analyses, 
genomic DNA was extracted using the QIAamp DNA 
FFPE tissue kit (Qiagen, Venlo, Netherlands) from FFPE 
samples obtained by the initial biopsy (29 cases) or re-
biopsy (eight cases), then activating EGFR mutations 
were detected by Therascreen EGFR (Qiagen, Venlo, 
Netherlands).
BNA-clamped F-PHFA for detection of EGFR 
mutations in cfDNA and/or genomic DNA
In the present study, we utilized artificial nucleic 
acid, BNA as clamping reagents and probes in real-time 
PCR procedure to realize more mutation-specific and 
stable detection assay. BNA-clamped real-time PCR 
were performed using a CFX96 real-time PCR system 
(Bio-Rad, Pleasanton, CA). Samples were amplified with 
BNA Real-time PCR Mutation Detection Kit for EGFR 
(Riken Genesis, Tokyo, Japan). By using the amplicon 
and labeled dsDNA, F-PHFA was performed as previously 
reported [26]. Thermal condition was 10-min denaturation 
at 95° C, cooling to 65° C at ramp rate 0.5° C/10 seconds. 
The fluorescence intensities were measured at prescribed 
time points. The following equation was used to evaluate 
the Index in the F-PHFA: 
Index (%) = (F [90° C] − F [65° C (after)])/(F [90° 
C] − F [65° C (before)]) × 100,
where F [90°C], F [65° C (after)] and F [65° C 
(before)] represent fluorescence intensities at 90° C, after 
F-PHFA reaction at 65° C and before F-PHFA reaction at 
65° C, respectively. According to the predefined thresholds 
of the Index for each mutation, the samples were evaluated 
as positive for the mutation.
BNA-clamped real-time PCR, ultra-deep 
sequencing with NGS and ddPCR for detection 
of EGFR mutations in cfDNA and/or genomic 
DNA
BNA-clamped real-time PCR were performed as 
aforementioned. After each reaction, the change in cycle 
threshold (ΔCt) was calculated by the Ct score of the 
probe set. If ΔCt was less than the assay performance 
characteristics, the samples were evaluated as positive 
for the mutation. Deep sequencing with NGS was 
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performed based on the methods as previously reported 
[25]. Briefly, samples were amplified with separate 
primer sets (wild type and each EGFR mutation), 
and then libraries were constructed and purified by 
QIA quick PCR Purification Kit (Qiagen, Venlo, 
Netherlands). Purified libraries were diluted to 8.0 pM 
and the pooled libraries were re-loaded into the Ion 
Chef instrument, then templates were prepared using 
Ion PGM Template OT2 200 Kit (Life Technologies, 
Carlsbad, CA). Finally, templates were loaded into the 
316v2 chip and sequenced on the Ion PGM Sequencing 
200 Kit v2 (Life Technologies, Carlsbad, CA). The 
PGM sequencing data were analyzed by the Ion Torrent 
Software (Life Technologies, Carlsbad, CA). The ddPCR 
assays (L858R, Del 19 and T790M) were performed 
using a QX200 Droplet Digital PCR System (Bio-Rad 
Laboratories Inc., Hercules, CA). Allele frequencies 
were analyzed using QuantaSoft v1.6 (Bio-Rad 
Laboratories Inc., Hercules, CA).
Evaluation of the detection limit of each cfDNA 
analysis method
To determine the sensitivity (detection limits) for 
the screening of EGFR mutations in each analysis method, 
cfDNAs obtained from the plasma of NSCLC patients 
were mimicked by mutated EGFR DNA reference standard 
(Horizon Discovery, Cambridge, UK) serially diluted into 
wild-type DNA reference standard (Horizon Discovery, 
Cambridge, UK). For NGS, DNA samples containing 
mutant DNA at 0.025%, 0.05%, 0.1%, 0.5% and 1% were 
subjected to PCR. For F-PHFA, DNA samples containing 
mutant DNA at 0.025%, 0.05%, 0.1% and 0.2% were 
subjected to PCR. For ddPCR, DNA samples containing 
mutant DNA at 0.05%, 0.1% and 0.5% were subjected to 
PCR. The copy numbers of plasmid DNA per one reaction 
were adjusted to 15,000, 60,000 and 15,000 copies in 
NGS, F-PHFA and ddPCR, respectively. The detection 
limit was defined as the mutation frequency which were 
evaluated as positive more than one time by repeated 
analysis.
Statistical analysis
The correlations between isolated cfDNA amounts 
and sum of diameters of target lesions or PFSs were 
evaluated by the Spearman’s rank correlation test. The 
correlations between patient characteristics and isolated 
cfDNA amounts were estimated by the Mann-Whitney 
U Test. The P-values less than 0.05 were considered 
significant. All analyses were performed using EZR 
(Saitama Medical Center, Jichi Medical University, 
Saitama, Japan), which is a graphical user interface for 
R (The R Foundation for Statistical Computing, Vienna, 
Austria) [27].
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